Erythroblastopeni forårsaget af neutraliserende antierythropoietin antistoffer er blevet rapporteret i forbindelse med erythropoietinterapi, herunder NeoRecormon.
Pure red cell aplasia caused by neutralising anti-erythropoietin antibodies has been reported in association with erythropoietin therapy, including NeoRecormon.